Chart-Typ:
Zeitraum:
| Trina Solar completes sale of 5 GW U.S. module plant to T1 Energy | Trina Solar has completed the sale of its 5 GW US solar module factory to T1 Energy, exiting direct manufacturing while retaining a minority equity stake.Trina Solar has completed the sale of its 5... ► Artikel lesen |
| T1 Energy signs 900 MW US solar module deal with Treaty Oak Clean Energy | T1 Energy has signed a three-year deal to supply a minimum of 900 MW of US-made modules while scaling its Austin cell fab to 5 GW annual capacity.From pv magazine USA US solar cell and module manufacturer... ► Artikel lesen |
| T1 Energy Inc.: T1 and Treaty Oak Execute Strategic Partnership | AUSTIN, Texas and NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") announced this morning the Company has signed a three-year contract to... ► Artikel lesen |
| Niu Technologies Announces Unaudited Third Quarter 2025 Financial Results | -- Third Quarter Revenues of RMB 1,693.9 million, increase 65.4% year over year -- Third Quarter Net Income of RMB 81.7 million, compared to net loss of RMB 40.9 million in the same period of last... ► Artikel lesen |
| NIU TECHNOLOGIES: Beim Absatz ein matt-glänzendes Q3. | Der 2014 gegründete chinesische Hersteller elektrisch betriebener Zweiräder (Sortiment von Motorrädern über Scooter bis Bikes) meldete für das dritte Quartal ein Absatzplus von 49 % zum Vorjahr nach... ► Artikel lesen |
| Niu Technologies Provides Third Quarter 2025 Sales Volume Update | BEIJING, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU", or "the Company") (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease | RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GIFTIFY INC finden Sie auf Wallstreet Online.